Valneva’s COVID-19 Vaccine Approved In UK While Talks Continue Over Scrapped Supply Deal
The MHRA has become the first regulatory agency worldwide to grant a marketing authorization for the inactivated whole virus COVID-19 vaccine, VLA2001.
You may also be interested in...
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.
Valneva expects its vaccine candidate to be approved this month. Meanwhile, the core functions of the UK’s Vaccine Taskforce are to be transferred to the UK Health Security Agency and the Office for Life Sciences.
Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.